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OBJECTIVES We sought to assess the efficacy of biventricular pacing with respect to both peak and
submaximal measures of exercise in patients with New York Heart Association class III heart
failure (HF) and intraventricular conduction delay in a randomized, blinded study.
BACKGROUND Submaximal and maximal changes in exercise capacity need evaluating in this patient
population with this novel therapy.
METHODS Graded exercise and 6-min walk tests were performed in patients randomized to three months
each of active (atrio-biventricular) and inactive pacing. Minute ventilation (VE), oxygen
uptake (VO2), ventilated carbon dioxide (VCO2) and heart rate were measured in patients
achieving a respiratory quotient 1 (n  30). Oxygen pulse, anaerobic threshold (AT) and
ventilatory efficiency (VE/VCO2) were calculated.
RESULTS Active biventricular pacing increased peak VO2 (15.8  4.3 vs. 14.4  4.6 ml/kg/min, p 
0.02), exercise time (501  223 s vs. 437  233 s, p  0.001) and oxygen pulse (9.3  2.8
vs. 8.1  3.1 ml/beat, p  0.01) compared with inactive pacing. The submaximal measures
of exercise capacity significantly increased with active pacing: AT (11.2  4.1 ml/kg/min vs.
9.5  2.3 ml/kg/min, p  0.02) and 6-min walk (414  94 m vs. 359  94 m, p  0.001).
Minute ventilation/ventilated carbon dioxide improved (32  9 vs. 36  11, p  0.03) with
normalization of the VE/VCO2 slope in 59% of patients (chi-square test, p  0.002) with
active pacing.
CONCLUSIONS Biventricular pacing may improve maximal and submaximal exercise capacity in patients with
advanced HF and intraventricular conduction delay. (J Am Coll Cardiol 2003;41:582–8)
© 2003 by the American College of Cardiology Foundation
Patients with severe heart failure (HF) experience consid-
erable disability despite important advances in medical
therapy (1–4). Simultaneous pacing of the left ventricle
(LV) and right ventricle (biventricular pacing) has been
proposed as an advantageous electrical therapy that, in
patients with severe HF and intraventricular conduction
delay (5), improves ventricular coordination and hemody-
namics (6–9). The feasibility of permanent implantation has
been proven, and clinical improvement has been suggested
in observational studies (10).
The Multisite Stimulation in Cardiomyopathy Study
(MUSTIC) is a multicenter study that compared active
biventricular pacing with no pacing in a prospective, ran-
domized, single-blind, crossover study. The primary and
secondary end points, including peak oxygen uptake (VO2)
with exercise, have been recently published with an Appen-
dix list of participants of the MUSTIC study (11). Patients
with severe HF tend to perform daily tasks that are more
related to submaximal measures of exercise. Information
from metabolic measures during submaximal exercise—
anaerobic threshold (AT) and ventilatory response to exer-
cise—may be more appropriate than maximal measures
when comparing the efficacy of any given therapeutic
strategy. The slope of minute ventilation (VE) per unit of
ventilated carbon dioxide (VCO2), a measure of ventilatory
drive, is also a powerful index of prognosis for patients with
moderate to severe HF—the higher the slope the worse the
outcome, generally (12,13). We studied the detailed cardio-
pulmonary exercise data in the patients from the MUSTIC
study to compare the effect of active biventricular pacing
with no pacing on both maximal and submaximal measures
of exercise.
METHODS
Patient population. Patients included in this study were in
New York Heart Association (NYHA) class III HF, receiv-
ing optimal medical therapy at the maximal tolerated dose,
and in a stable condition for 1 month (no NYHA class
changes, no hospitalization for HF, and no change in
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medication). Patients had an echocardiographic LV end
diastolic diameter 60 mm, a distance of 450 m in the
6-min walk test, and an ejection fraction 35% on angiog-
raphy or scintigraphy. Patients had to be in sinus rhythm
with an intrinsic QRS duration of 150 ms. Informed
consent was obtained from the patients, and local ethics
approval was obtained at each investigational center.
Patients were excluded if they were suspected of having
acute myocarditis or had hypertrophic or restrictive cardio-
myopathy, a systolic blood pressure 160 mm Hg or
diastolic blood pressure 95 mm Hg despite treatment,
symptomatic or sustained ventricular tachycardia, unstable
coronary symptoms (angina or myocardial infarction) within
three months or a planned revascularization, correctable
valve disease, inability to walk, or a conventional pacemaker
indication.
Study design. The MUSTIC study design was a random-
ized, crossover phase design comparing biventricular stim-
ulation with no ventricular stimulation (11). Treatment
order was randomized according to a complete randomized
block design. Programming was randomized to DDD
biventricular or VVI 40 and changed to the alternative
program mode at the crossover stage between phases 1 and
2 in each individual. Cardiopulmonary exercise testing
(CPET), 6-min distance walked, and quality of life (QOL)
evaluation were performed at enrollment (to familiarize
patients with the tests), randomization (2 weeks after
implantation), phase 1 (12 weeks after randomization) and
phase 2 (24 weeks after randomization). Patients were
blinded to the programmed pacemaker settings. During the
crossover phases, changes in diuretic therapy were permitted
if required; but dosage was constant for other medications,
and no new drug for congestive HF was added during the
study.
Implantation and programming of pacemaker. Before
lead placement, coronary sinus venography was undertaken
to define the anatomy. Left ventricular lead 2187 or 2188
(Medtronic Inc., Minneapolis, Minnesota), right ventricular
and right atrial leads were introduced into either the
cephalic or subclavian veins. Optimal LV lead placement
was mid-lateral in a wedged position. Other locations
(antero-lateral, posterior) were acceptable. The right ven-
tricular lead was anatomically as far as possible from the LV
lead. Either InSync 8040 (Medtronic) or Chorum MSP
(ELA Medical, Montrouge, France) was implanted. The
pacemaker was programmed to a basic rate of 40 beats/min
and upper limit 85% of the age–gender maximum predicted
heart rate (HR). The atrioventricular delay was optimized
using echo Doppler, selecting optimal filling time and aortic
outflow velocity time integral. Active pacing was defined as
pacing configuration DDD biventricular and inactive pacing
defined as pacing configuration VVI 40.
Outcomes measured. Each patient performed a supervised
CPET to maximum tolerance either on a treadmill or
cycloergometer according to the facilities at each center.
Graded exercise bicycle testing was performed on an elec-
tromagnetically braked cycle using a 20 W start and 10 W
min incremental increase. Treadmill exercise testing was
performed using a modified Bruce protocol. All tests in a
given patient were performed with the same equipment and
protocol in each phase of the study. A light meal could be
eaten up to 3 h before the test. Gas exchange measurements
(Medical Graphics Corporation, St. Paul, Minnesota) were
made during 3 min of rest, followed by progressively
increasing work rate exercise and 5 min of recovery. Pulse
oximetry, HR, 12-lead ECG, and cuff blood pressure were
monitored and recorded. Criteria for termination were
intense dyspnea, exhaustion, angina pectoris, fall in blood
pressure, non-sustained or sustained ventricular tachycardia,
poorly tolerated atrial tachyarrhythmias, or achievement of
maximal predicted HR.
Minute ventilation, VO2, VCO2 and other exercise
variables were computer calculated breath by breath, inter-
polated second by second, and averaged over 10-s intervals
(14). Data were collected from all investigational centers
and analyzed centrally to avoid center bias and to standard-
ize interpretation. Each test was coded so that the analyzers
were blinded to the mode of pacing. For the exercise data to
be analyzed, detailed 10 s plotted data had to be available,
and only patients achieving a respiratory quotient 1 were
included.
The achieved peak VO2 results were expressed as ml/kg/
min. The O2 pulse is the quotient of the VO2 (in ml) over
HR and is determined by stroke volume and the arterio-
venous (AVO2) difference (14). The AT was determined by
plotting VCO2 against VO2 (V slope method) (15) and
then plotting VE/VCO2 with VO2 (dual criteria AT) (14)
if needed. The results of the AT were expressed as the value
of VO2, in ml/kg/min, at which the AT was reached. The
VE/VCO2 slope was calculated as the slope of the regres-
sion line relating VE to VCO2 during exercise testing before
the AT and was used as an index of the ventilatory response
to exercise (14). The non-linear portion of this relationship
after the onset of the acidotic drive to ventilation was
excluded (16).
The 6-min walk test was performed according to the
published recommendations (17,18). Baseline evaluation
with a run in test followed by two further tests was
Abbreviations and Acronyms
AT  anaerobic threshold
CPET  cardiopulmonary exercise test
HF  heart failure
HR  heart rate
LV  left ventricle, ventricular
MUSTIC  Multisite Stimulation in Cardiomyopathy
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NYHA  New York Heart Association
QOL  quality of life
VCO2  ventilated carbon dioxide
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performed at 24-h intervals. At each of the other phases of
assessment, two tests were performed with an interval of at
least 3 h between them. The maximum difference between
the two tests was 15%, and the value recorded the mean of
the results of the two tests. Quality of life was assessed as
part of the MUSTIC study, using the Minnesota Living
With Heart Failure questionnaire at each phase of evalua-
tion (19). The questionnaire contains 21 questions regard-
ing patients’ perceptions of the effects of HF on their daily
lives. Each question is rated on a scale of 0 to 5, producing
a total score between 0 and 105. The higher the score, the
worse the QOL.
Statistical analysis. The sample size for the MUSTIC
study was calculated based on an estimated 10% increase in
the distance walked in 6 min with active pacing. For a study
with a 95% confidence level and 95% power, the total
sample size needed was estimated to be 22 patients. Patients
acted as their own controls. Standard equations were used to
predict actual and percent-predicted values for CPET mea-
sures (14). Period and crossover effects were checked before
the efficacy of treatment was evaluated. The a priori design
of this study was intended to compare measures between
inactive and active pacing; therefore, two-tailed paired
Student t tests were used. Data are presented as mean 
standard deviation. Software used was SPSS version 9
(SPSS Inc., Chicago, Illinois). A significant change was
defined as an  of p  0.05. Simple individual linear
regression analyses were performed by the Pearson correla-
tion coefficient (r) between individual variables.
RESULTS
Patient enrollment and characteristics. Sixty-seven pa-
tients from 16 centers were enrolled into the MUSTIC
study (11). Of those, five patients died before completing
the crossover phases, seven had technical difficulties with
pacemaker implantation, four withdrew their consent, and
three were withdrawn because of the development of an
exclusion criterion. Forty-eight patients completed the
crossover phases. In six patients complete exercise data sets
were not available, and in seven patients inadequate studies
had been performed for one or more of the four phases of
the study. Therefore, detailed 10-s interpretable plotted
data were available for analysis in 35 patients. Only patients
with a respiratory quotient 1 at peak exercise in every
phase, indicating satisfactory exercise effort, were then
included (n  30). Sixteen patients were randomized to the
first three months active then inactive pacing, and 14
patients to the first three months inactive then active pacing.
All the patients terminated exercise because of either dys-
pnea or exhaustion.
Twenty-five of the patients analyzed were male. The
mean age was 64  10 years (range 38 to 79). All were in
NYHA class III HF. Baseline QRS duration was 173  18
ms, LV end diastolic diameter 73  11 mm, and LV
ejection fraction 23  8%. Sixteen patients had idiopathic,
and 14 ischemic, etiology for HF. Drug treatment was loop
diuretic (100%), angiotensin-converting enzyme inhibitor
or angiotensin receptor blocking agent (96%), digoxin
(40%), beta-blocker (37%), amiodarone (30%), and spirono-
lactone (30%). The mean dosage of each drug was the same
at baseline and at each assessment. At randomization, the
peak exercise measures were peak VO2 14.3  4.0 ml/kg/
min, exercise time 432  190 s, respiratory quotient 1.14 
0.10, HR 125  24 beats/min. Submaximal measures of
exercise were AT 9.8 3.5 ml/kg/min, 6-min walk distance
366  79 and VE/VCO2 40  12.
Measures of peak exercise. Individual changes in peak
measures of exercise between active biventricular pacing and
inactive pacing are shown in Table 1. The peak VO2 was
significantly increased at the end of the active pacing phase
compared with the end of the inactive phase (15.8  4.3
ml/kg/min vs. 14.4  4.6 ml/kg/min, p  0.02). An
improvement was seen in the peak VO2 in 24 of 30 patients
with active pacing compared with inactive pacing. At the
end of the inactive phase, the predicted peak VO2 was
40% of the predicted peak VO2 in five patients, and this
improved with biventricular pacing to only one patient with
a peak VO2 40% of that predicted (chi-square test, p 
0.05). The maximum O2 pulse (VO2/HR) was significantly
improved between the inactive phase and active pacing
phase, from 8.1  3.1 ml/beat to 9.3  2.8 ml/beat, p 
0.002. The exercise time was significantly increased at the
end of the active pacing phase compared with the end of the
inactive phase (501  223 s vs. 437  233 s, p  0.001).
Change in exercise time correlated with change in peak VO2
(r  0.57, p  0.001).
Measures of submaximal exercise. The AT significantly
increased from 9.5  2.3 ml/kg/min at the end of the
inactive pacing phase to 11.2 4.1 ml/kg/min at the end of
the active pacing phase, p  0.014 (Fig. 1). An improve-
ment in AT was observed in 23 of 28 (82%) patients, Table
2. Only 10 patients reached an AT in excess of 40% of the
maximum predicted VO2 during the inactive phase. This
increased to 18 patients achieving an AT in excess of 40% of
the maximum predicted VO2 with pacing (chi-square test, p
 0.03). No patients reached an AT in excess of 50% of the
maximum predicted VO2 during the inactive phase, com-
pared with 12 patients with biventricular pacing. Six-minute
distance walked showed a significant increase between the
actively paced and inactive phases (active 414  94 m vs.
inactive 359  94 m, p  0.001), Figure 1. The change
between the active and inactive phases in 6-min walk
distance correlated with the change in AT (r  0.53, p 
0.004).
The VE/VCO2 slope (below the AT) was significantly
lower (that is, ventilatory efficiency increased) at the end of
the active pacing phase compared with the end of inactive
phase (32  9 vs. 36  11, p  0.03), Figure 1. Seventeen
of the patients had a VE/VCO2 slope 30 (above normal)
in the inactive phase, compared with seven patients 30
with biventricular pacing (chi-square test, p  0.002). The
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change in VE/VCO2 correlated with change in exercise
time (r  0.55, p  0.01) between the active and inactive
phases.
QOL. The QOL score was significantly improved during
the inactive to the active phase (39  20 to 27  22, p 
0.002). A significant correlation was seen between the
change in QOL and change in 6-min walk distance (r 
0.61, p  0.001); a weak correlation was observed with
change in peak VO2 (r  0.34, p  0.07) and exercise
time (r  0.30, p  0.12). In those with a large reduction
in QOL score (10, n  15) the improvement in QOL
was more strongly correlated with changes in peak exercise
(peak VO2 r  0.57, p  0.03, exercise time r  0.49,
p  0.06).
DISCUSSION
This study demonstrated that biventricular pacing in pa-
tients who are already receiving optimal medical therapy
significantly increased measures of both maximal and sub-
maximal exercise, extending the published findings of the
MUSTIC study (11). A high concordance has been shown
between improvement in exercise capacity and symptoms,
supporting the view that exercise testing is a useful adjunct
in assessing the clinical response of patients with symptom-
atic HF to therapeutic interventions (20). Exercise levels are
dependent on several factors, including patient motivation,
symptomatic limitation, premature cessation of exercise due
to apprehension regarding the onset of symptoms and the
level of conditioning (most patients with HF are naturally
deconditioned). A general improvement in daily life activ-
ities with biventricular pacing may lead to increased physical
training, which helps improve the measures of exercise.
Such effects, however, should be countered by the use of
patients who were blinded to the phase of study, as their
own controls. The importance of the design of the study to
accurately assess changes in exercise was highlighted by a
comprehensive review of studies of angiotensin-converting
enzyme inhibitors and exercise capacity (20). Our protocol
followed the standards recommended, which include a
follow-up period of at least 12 weeks and a consistent
method of exercise testing for the individual patient
throughout the study. The crossover design with patients












1 13.5 245 131 1.58 13.6 269 120 1.75
2 10.8 195 107 1.01 10.9 287 104 1.18
3 16.8 497 108 1.08 13.7 480 88 1.13
4 15.2 366 113 1.09 16.4 325 89 1.04
5 28.5 170 82 1.11 28.8 205 92 1.12
6 16.0 330 82 1.07 21.5 660 92 1.17
7 13.5 429 104 1.14 14.2 411 141 1.18
8 13.8 512 110 1.10 15.0 567 125 1.01
9 20.3 420 136 1.22 22.4 541 148 1.27
10 12.9 141 111 1.24 17.0 381 135 1.66
11 13.8 465 133 1.05 15.6 480 114 1.04
12 13.4 800 161 1.20 15.2 640 129 1.10
13 9.9 197 129 1.13 11.7 168 116 1.06
14 22.6 286 106 1.41 20.1 277 111 1.32
15 13.2 377 148 1.14 18.6 507 138 1.34
16 14.0 745 133 1.04 15.2 785 127 1.04
17 20.8 339 129 1.29 17.7 471 119 1.08
18 11.8 894 125 1.01 15.3 867 135 1.03
19 11.6 600 133 1.10 16.8 720 133 1.07
20 11.1 353 125 1.18 11.5 496 113 1.14
21 8.9 191 98 1.34 9.2 211 110 1.10
22 10.4 270 98 1.08 12.1 390 108 1.08
23 11.4 730 157 1.08 15.0 928 163 1.13
24 8.9 495 133 1.31 7.5 516 100 1.60
25 14.3 330 101 1.14 16.4 373 109 1.18
26 22.7 661 110 1.11 15.0 689 129 1.12
27 17.6 259 166 1.29 19.1 315 180 1.10
28 10.8 960 158 1.01 16.0 1031 126 1.90
29 13.2 840 175 1.04 21.5 840 145 1.21
30 11.2 410 150 1.09 10.8 470 109 1.10
Mean 14.4 437 123 1.20 15.8 501 123 1.16
p value 0.024 0.001 NS NS
ET  exercise time, Pt  patient, RQ  respiratory quotient
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serving as their own controls effectively doubles the power of
the study and reduces the number of centers entered,
leading to greater uniformity in application of CPET. Most
of the drug treatments for HF have resulted in some
improvement in exercise capacity (21–25). The effect of
biventricular pacing—to increase peak VO2 by 10% and
duration of exercise by 16%—is similar to or better than the
effect on exercise demonstrated in most drug studies. In this
study of biventricular pacing, similar increases in peak
measures of exercise were observed in patients who were
already receiving maximal medical therapy.
The effect of increase in peak VO2 was independent of
HR response, as shown by the significant increase in O2
pulse (VO2 /HR). The O2 pulse in this patient group was
lower than in normal subjects (normal 15 ml/beat), as
would be expected in a group of patients with advanced HF
(14). Exercise capacity is reduced in HF patients not only
because of a decreased cardiac output response on exercise
leading to tissue hypoxia, which results in premature lactate
mediated metabolic acidosis, but also because of additional
peripheral adaptations leading to poor uptake of oxygen into
tissues (26). The increase in O2 pulse may be a result of a
higher stroke volume and/or improved uptake and utiliza-
tion of oxygen in the skeletal muscle beds. Each phase of the
trial lasted only three months, making it more likely that the
improvement observed with biventricular pacing was related
to an increase in stroke volume rather than to an increase in
peripheral oxygen extraction, which implies major changes
in the skeletal muscle characteristics and generally takes
longer. This would be consistent with the increase in stroke
volume observed with biventricular pacing in acute pacing
studies (8,27). Improved cardiac function with biventricular
pacing has been shown to be at diminished energy cost in
contrast to inotropic agents (28). We included all patients in
Figure 1. Comparison of measures of submaximal exercise during active and inactive pacing. Significant increases were observed in the distance walked in
6 min (meters, p 0.001) and anaerobic threshold (AT, ml/kg/min, p 0.02) during active pacing. A significant improvement was observed in the minute
ventilation/ventilated carbon dioxide (VE/VCO2, p  0.03). Black bars randomization; vertically lined bar  inactive pacing; horizontally lined bar
 active pacing.
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the analysis of O2 pulse regardless of whether chronotropic
incompetence was present, because chronotropic incompe-
tence is one of the mechanisms of functional limitation in
HF (29).
Submaximal measures of exercise. An important aim of
treatment for severe HF is to increase the ability of the
patient to perform the routine tasks of daily living, such as
walking and climbing stairs. Patients with advanced HF
perform a series of submaximal exercise tasks during normal
daily activity, and measures that reflect such activity may be
more useful than contrived exercise tasks in assessing the
efficacy of treatment. Improvements in submaximal indices
were seen with active pacing for three months: AT increased
18%, 6-min walk distance increased 15%, and VE/VCO2
slope decreased 11%.
The AT provides a measure of the adequacy of cardio-
vascular function in response to an exercise stimulus (30).
Improvement in AT was observed in 82% of patients with
biventricular pacing. Notably, without pacing the AT was
not greater than 50% of predicted peak VO2 in any patient,
but this threshold was exceeded in 12 patients with pacing.
This may be of particular benefit in reducing muscular
fatigue, which has been demonstrated to be an important
determinant of exercise limitation in HF (26).
The 6-min walk test is another measure of submaximal
exercise capacity. Although it provides no information for
assessing the mechanism of exercise limitation, it is a simple
and reproducible indicator of ability to perform tasks of
daily living shown to be particularly useful in the assessment
of treatments—for example, in the Studies of Left Ventric-
ular Dysfunction (SOLVD) trial (31). With active pacing in
patients considered to be receiving optimal pharmacologic
therapy, there was an additional increase in walk distance
similar to the improvement in metabolic gas exchange
indices of exercise capacity, which correlated with improve-
ment in QOL.
The VE/VCO2 provides a non-invasive assessment of the
appropriateness or efficiency of VE (tidal volume  respi-
ratory rate/min) during exercise, and it may contain prog-
nostic information that extends beyond that of peak VO2
(12,13). In normal subjects the VE/VCO2 slope is 30 in
the region below the AT (14). In HF this slope is generally
increased, implying increased ventilatory drive, and this was
observed in our patient group. However, biventricular pac-
ing normalized the VE/VCO2 slope during exercise in 59%
of the patients receiving optimized medical therapy for HF.
The slope of VE/VCO2 is determined by two factors: 1)
behavior of arterial CO2 tension during exercise and 2) the
fraction of tidal volume, Vt, that goes into dead space, Vd.
The mechanisms responsible for exercise hyperpnea have
not yet been fully elucidated. Current information suggests
that a major source for a steep VE/VCO2 slope in conges-
tive HF is increased non-uniformity of ventilation perfusion
(V/Q) causing inefficient gas exchange, although many
other factors may cause the increased ventilatory response to
exercise of patients with HF (32,33). Biventricular pacing
increases cardiac output (8) and reduces left atrial pressure
(27) leading to less pulmonary congestion, which may lead
to improved ventilation perfusion matching. Such changes
would be expected to reduce ventilation perfusion mismatch
and may account for the dramatic improvement in ventila-
tory drive observed with biventricular pacing.
Study limitations. Peak exercise time during a progres-
sively loaded test is dependent on motivation from the
patient and investigator. The design of this study, with each
patient being his/her own control and being blinded to the
mode of pacing, attempted to counter any effect of motiva-
tion. Because this was a multicenter study, not all exercise
tests had all indices available—hence, the reduction in
numbers from those enrolled to those finally included. The
follow-up period for this study was relatively short.
CONCLUSIONS
Biventricular pacing can significantly improve both maximal
and submaximal measures of exercise, which may better
reflect exercise capacity during normal daily activities. The
Table 2. Measures of Submaximal Exercise During Inactive and













1 20 197 21 370
2 38 305 35 319
3 41 414 51 468
4 34 305 34 257
5 nd 153 25 212
6 26 207 32 474
7 49 470 48 467
8 nd 388 nd 393
9 50 351 50 369
10 28 188 67 442
11 48 366 54 448
12 34 363 39 405
13 48 355 42 365
14 28 351 31 400
15 32 438 44 477
16 49 327 71 332
17 35 380 71 542
18 31 428 47 456
19 45 570 45 670
20 25 435 26 423
21 32 330 54 291
22 36 391 50 517
23 48 324 63 392
24 24 346 25 328
25 44 305 55 318
26 46 412 58 469
27 38 361 41 478
28 39 403 22 403
29 38 550 55 550
30 33 377 26 402
Mean 37 359 44 414
p value 0.002 0.001
AT  anaerobic threshold; nd  not determinable; Pt  patient.
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increased ventilatory drive of patients with HF was reduced
with biventricular pacing. Changes observed were consistent
with improvements in QOL. Biventricular pacing is a
potentially useful therapy for patients with severe HF and
intraventricular conduction delay.
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